NCT06787989 - BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

April 30, 2027

Conditions

Refractory Immune Cytopenia

Interventions

BIOLOGICAL

BCMA-CD19 cCAR T cells

• BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Chengdu